Sopharma AD works to ensure health equity and access to quality and effective treatment for patients in all its markets through affordable high quality medicines and widening its generic portfolio.
The company transferred its medicine donations policy to a different stage in order to ensure the right treatment for every different case in collaboration with our partner BCAF and other partners.
- To ensure the access to a modern treatment
Sopharma AD supports one of the most accessible medicines in our markets and produce small packages.
Sopharma has a 3% share on the Bulgarian pharmaceutical market in terms of value and a 11% share in terms of sold quantity (units).
- Sopharma AD spends more resources on science and progress
The products Sopharma AD already manufactures are with European quality, since all plants comply with the highest contemporary requirements.
The company invests, when possible, in process and technology optimization, and spend more resources and attention on science and progress, including on new products or new forms of already existing products.
- 6 medicinal products / active substances have been transferred / are in the process of transfer. 10 production processes / technologies have been validated / optimized.
- Sopharma AD invests in developing generics
Sopharma AD widens its generic portfolio. In Europe generics become increasingly important and this is the way to decrease costs and save resources to be invested in innovation.
Pharmaceutical development is carried out of 4 new products for the Company.
The positions of the main competitors of the company in Bulgaria are as follows:
Bulgarian market share
In units (%)
|Share of the total Bulgarian market in units as at 31.03.2021%|
|Novartis||3.5% in units|
|Roche||0.2% in units|
|Actavis||9.6% in units|
|Bayer||2% in units|
|Sopharma||11.5% in units|
|Abbvie||0% in units|
|Sanofi-Aventis||2% in units|
|Astrazeneca||0.5% in units|
|Pfizer||0.6% in units|
|Merck||0.8% in units|
In values (%)
|Share of the total Bulgarian market in value as at 31.03.2021 %|